ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sarina Tanimoto Sells 100,000 Shares

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Sarina Tanimoto sold 100,000 shares of the business’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $9.28, for a total transaction of $928,000.00. Following the transaction, the insider now directly owns 1,647,447 shares in the company, valued at approximately $15,288,308.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Sarina Tanimoto also recently made the following trade(s):

• On Friday, March 22nd, Sarina Tanimoto sold 2,343 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.02, for a total transaction of $21,133.86.
• On Thursday, March 14th, Sarina Tanimoto sold 444 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.00, for a total transaction of $3,996.00.
• On Wednesday, February 28th, Sarina Tanimoto sold 98,778 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.02, for a total transaction of $890,977.56.
• On Monday, February 26th, Sarina Tanimoto sold 700 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.01, for a total transaction of $6,307.00.

ARS Pharmaceuticals Trading Down 1.3 %

NASDAQ SPRY traded down $0.12 on Wednesday, hitting $9.06. 456,562 shares of the company were exchanged, compared to its average volume of 617,663. The firm has a 50 day moving average of $8.69 and a two-hundred day moving average of $6.23. The company has a market cap of $874.29 million, a P/E ratio of -15.89 and a beta of 0.83. ARS Pharmaceuticals, Inc. has a 1-year low of $2.55 and a 1-year high of $11.27.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.07. Research analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.69 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on SPRY shares. Wedbush restated an “outperform” rating and issued a $19.00 target price on shares of ARS Pharmaceuticals in a research note on Monday, March 11th. William Blair upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 20th. SVB Leerink upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $6.00 to $18.00 in a research note on Tuesday, March 5th. Finally, Leerink Partnrs upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 5th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC raised its holdings in ARS Pharmaceuticals by 22,300.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,600 shares of the company’s stock worth $31,000 after purchasing an additional 5,575 shares during the last quarter. AJOVista LLC bought a new stake in ARS Pharmaceuticals during the 4th quarter worth about $43,000. Tower Research Capital LLC TRC bought a new stake in ARS Pharmaceuticals during the 2nd quarter worth about $64,000. Wells Fargo & Company MN bought a new stake in ARS Pharmaceuticals during the 2nd quarter worth about $64,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in ARS Pharmaceuticals by 352.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,105 shares of the company’s stock worth $61,000 after purchasing an additional 8,652 shares during the last quarter. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.